...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Surgical Oncology >Permanent interstitial 125 I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
【24h】

Permanent interstitial 125 I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment

机译：永久性间质性125 I种子植入作为多学科治疗后小儿复发或转移性软组织肉瘤的抢救疗法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The management of pediatric recurrent or metastatic soft tissue sarcoma after multimodal treatment remains challenging. We investigated the feasibility, efficacy, and morbidity of permanent interstitial 125I seed implantation under image guidance as a salvage treatment for pediatric patients with recurrent or metastatic soft tissue sarcoma. This was a retrospective study of 10 patients who underwent percutaneous ultrasound or computed tomography (CT) guided permanent 125I seed implantation. Postoperative dosimetry was performed for all patients. Actuarial D90 was 121–187.1?Gy (median, 170.3?Gy). The number of 125I seeds implanted was 6–158 (median, 34.5), with a median specific activity of 0.7?mCi per seed (range, 0.62–0.8?mCi); total activity was 4.2–113.76?mCi. Follow-up time was 6–107?months (median, 27.5?months); no patients were lost to follow-up. The overall response rate (complete response?+?partial response) was 8/10 (80?%), including two patients with complete response (CR) (20?%) and five patients with partial response (PR) (60?%). Local control rates after 1 and 2?years were 70.1 and 62.3?%, respectively, with a mean local control time of 70.6?months (95?% confidence interval (CI) 45.1–96.0). Survival rates after 1 and 2?years were 68.6 and 57.1?%, respectively, with a mean survival time of 65.3?months (95?% CI 34.1–96.5). Three patients died from distant metastasis; one died from local recurrence 12?months after seed implantation. Three patients suffered a grade I skin reaction and one developed ulceration. No severe adverse neurologic sequelae or blood vessel damage occurred. Image guided permanent interstitial 125I seed implantation as a salvage treatment appears to have a satisfactory outcome in children with recurrent or metastatic soft tissue sarcoma.
机译：多模式治疗后小儿复发性或转移性软组织肉瘤的治疗仍然具有挑战性。我们研究了在图像指导下永久性间质性125I种子植入作为挽救性治疗复发或转移性软组织肉瘤的儿科患者的可行性，疗效和发病率。这是一项回顾性研究，对10例行经皮超声或计算机断层扫描（CT）指导的125I永久性种子植入患者进行了回顾性研究。对所有患者进行术后剂量测定。精算D90为121–187.1？Gy（中位数为170.3？Gy）。植入的125I种子数量为6至158（中位数为34.5），每颗种子的中位数比活性为0.7？mCi（范围为0.62〜0.8？mCi）;总活性为4.2–113.76？mCi。随访时间为6-107个月（中位数为27.5个月）;没有患者失去随访。总体缓解率（完全缓解+部分缓解）为8/10（80％），其中包括2例完全缓解（CR）（20 %%）和5例部分缓解（PR）（60 %%） ）。 1年和2年后的本地控制率分别为70.1％和62.3％，平均本地控制时间为70.6个月（95％置信区间（CI）为45.1–96.0）。 1年和2年后的生存率分别为68.6和57.1％，平均生存时间为65.3个月（95％CI 34.1–96.5）。 3例患者死于远处转移。种子植入后12个月，一名死于局部复发。 3名患者发生了I级皮肤反应，其中1名发生了溃疡。没有发生严重的不良神经后遗症或血管损伤。在复发性或转移性软组织肉瘤患儿中，以影像引导的永久性125I种子间质植入作为挽救治疗似乎具有令人满意的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号